Welcome to our dedicated page for Nano Labs SEC filings (Ticker: NA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nano Labs Ltd filings document its foreign private issuer current reports on Form 6-K, including press releases incorporated by reference into registration statements. These records cover financial results, cryptocurrency holdings and fair-value changes, product announcements for iPollo and OpenClaw, and strategic initiatives tied to Web 3.0 infrastructure.
The filings also record capital and governance matters, including share repurchase activity, annual general meeting proposals, amendments to the memorandum and articles of association, Class B ordinary share voting rights and the appointment of an independent registered public accounting firm.
Nano Labs Ltd. Schedule 13G filings disclose that a group of related filers led by Anson Funds Management LP collectively beneficially own 1,808,440 Class A Ordinary Shares, representing 8.7% of the 20,712,924 outstanding Class A shares reported in the issuer's June 30, 2025 prospectus supplement. The reporting group includes Anson Management GP LLC, Anson Advisors Inc., and individuals Tony Moore, Amin Nathoo and Moez Kassam, with shared voting and dispositive power over the shares and no sole voting or dispositive power reported. The filing states the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Nano Labs Ltd Schedule 13G discloses that Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B) and Waqas Khatri beneficially own 1,542,929 Class A ordinary shares, equal to 7.12% of the class as of June 30, 2025. That total comprises 590,548 shares held and 952,381 shares issuable on the exercise of warrants; the issuable shares are subject to a 9.99% beneficial ownership blocker. The filing cites 20,712,924 outstanding shares as of June 27, 2025, and reports sole voting and dispositive power over all 1,542,929 shares. The statement is signed by Waqas Khatri as Managing Member/Director for the reporting entities.
Nano Labs Ltd (NASDAQ: NA) filed Prospectus Supplement No. 4 to its May 2 2025 F-1 prospectus to register the potential resale of 652,174 Class A ordinary shares that may be issued upon exercise of outstanding warrants. The supplement incorporates three Form 6-K reports dated 2, 7 and 8 July 2025 and attaches the full warrant agreement, placement documents and Cayman legal opinions.
Key terms
- The warrants were issued in an April 11 2024 private placement and carry an $10.00 exercise price, initial exercise date of June 2025 and five-year term.
- The closing share price on 8 July 2025 was $7.86, below the exercise price, making near-term cash exercise unlikely.
- Exercise may be for cash or, under certain conditions, via cashless exercise. Anti-dilution provisions adjust the exercise price for stock splits, dividends, or dilutive issuances.
- No primary shares are being sold by the company; the selling shareholders will bear selling commissions. Nano Labs would receive proceeds only if warrants are exercised.
- The supplement reiterates high-risk disclosures and incorporates Cayman counsel’s opinion that the shares, when issued, will be validly issued, fully paid and non-assessable.
Investor implications
- Dilution potential: Full exercise would add ~2.3 % to current Class A float (based on ~28 m shares outstanding in last 20-F).
- Limited immediate impact: With the warrants currently out-of-the-money, cash inflow to Nano Labs is uncertain and resale volume depends on future share price performance.
- Legal clarity: Filing provides detailed warrant mechanics, tax opinions and confirms incorporation of recent 6-K disclosures into the registration statement.